Home
About
Publications Trends
Recent Publications
Expert Search
Archive
anti angiogenic therapy
What Cancers Are Treated with Anti-Angiogenic Therapy?
Anti-angiogenic therapy has been approved for use in a variety of cancers. These include:
-
Colorectal Cancer
-
Lung Cancer
-
Glioblastoma
-
Renal Cell Carcinoma
-
Ovarian Cancer
Each type of cancer may respond differently to anti-angiogenic therapy, and its use is often combined with other treatment modalities such as chemotherapy and radiation therapy.
Frequently asked queries:
What is Anti-Angiogenic Therapy?
How Does Angiogenesis Contribute to Cancer Growth?
What Are the Main Types of Anti-Angiogenic Agents?
What Cancers Are Treated with Anti-Angiogenic Therapy?
What Are the Side Effects and Limitations?
What Is the Future of Anti-Angiogenic Therapy?
What is the role of p53 in cancer prognosis?
How is MCD Diagnosed?
What Types of Work Accommodations Are Available?
What is Dysphagia?
How does EORTC ensure the quality of its research?
What is Regulation in Cancer?
What is the Impact of Stress Management on Cancer Risk?
What financial assistance is available for transportation costs?
How Do Molecular Probes Work?
What are the Limitations of PSA Testing?
What is Psychosocial Care?
What are Combination Treatments?
Can Bone Marrow Suppression Be Prevented?
Why Do Cancer Cells Upregulate Cholesterol Biosynthesis?
Top Searches
Brain Tumor
Breast cancer
cancer
Cancer Diagnostics
Cancer Genomics
Chemotherapy
hepatocellular carcinoma
Lung Cancer
Nanotechnology
Non-Hodgkin’s Lymphoma
Radiation-Induced Malignancies
Follow Us
Facebook
Linkedin
Youtube
Instagram
Partnered Content Networks
Relevant Topics
4D Segmentation
Alopecia
Atlas-based Segmentation
Automated Segmentation
B-cell malignancies
biomarkers
Brain Tumor
Brain Tumor Segmentation
Breast cancer
cancer
cancer diagnosis
Cancer Genome Atlas
Cancer genomics
Cancer treatment
CAR T-cell therapy
Carcinogenesis
cell adhesion
cell migration
cell-free RNA
chemotherapy
Chromatin remodeling genes
Chronic inflammation
CIAbimatoprost
circulating tumor cells
circulating tumor DNA
Co-morbidity
Combination therapy
Copy number variations
cytokine release syndrome
Deep Learning
Diagnosis challenges
diffuse large B-cell lymphoma
DNA damage
docetaxel-cyclophosphamide
Drug delivery
early detection
epirubicin-cyclophosphamide
exosomes
extracellular matrix
Fibrosis
Genetic alteration
Glioblastoma
Gold nanoparticles
Hepatocellular carcinoma
High Tumor
image-guided radiotherapy
Imaging Techniques
Immunosuppression
Immunotherapy
Integrative genomics
integrin inhibitors
Integrins
intensity-modulated radiation therapy
Keratinocyte
Lipid-based nanoparticles
Liquid biopsy
liver cancer
long-term cancer risks
Lung cancer
Machine Learning
Magnetic Resonance Imaging
metastasis
methyltransferase
minimal residual disease
MRI
Multi-modal Imaging
Multidisciplinary care
Mutual exclusivity analysis
Nanoparticles
Nanotechnology
neoadjuvant radiotherapy
neurotoxicity
Next-generation sequencing
nnovative Biomarkers
Non-Hodgkin’s lymphoma
non-invasive diagnostics
Novel Biomarkers for Brain Tumors
Novel Chemotherapy
Oncogenic transcription factors
oncological diseases
paclitaxel
Personalized medicine
Photobiomodulation therapy
Polymeric nanoparticles
portal vein tumor thrombus
precision medicine
Probabilistic Models
proton therapy
Radiation-induced malignancies
radiotherapy
refractory lymphoma
relapsed lymphoma
Risk factors
secondary cancer prevention
secondary cancers
Silver nanoparticles
stereotactic body radiation therapy
Targeted therapy
Tolerability
transarterial chemoembolization
Tuberculosis
tumor microenvironment
tumor progression
Voltage-gated sodium channels
Subscribe to our Newsletter
Stay updated with our latest news and offers related to Cancer.
Subscribe